AbD Serotec
Bio-Rad Q4 Revenues Spike 5 Percent
This story has been updated from a previous version to include comments from Bio-Rad's earnings call.
Bio-Rad Completes $70M Acquisition of AbD Serotec
NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.
Bio-Rad to Acquire AbD Serotec for $69.7M
NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced yesterday that it has signed a definitive agreement to acquire antibody manufacturer AbD Serotec for €53 million ($69.7 million) in cash.
Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.
Morphosys Inks Deal with Moredun, Roslin to Develop Protein Reagents for Veterinary Research
Premium
Morphosys announced that its AbD Serotec division has signed an agreement with the Moredun Research Institute and the University of Edinburgh's Roslin Institute to develop reagents for veterinary research.
Aug 5, 2011